ClinicalTrials.gg
CompletedNCT03263910Updated Aug 23, 2018

Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

A Phase 3 interventional study of NPO-11 and Placebo in Patients Undergoing Gastrointestinal Endoscopy, sponsored by Nihon Pharmaceutical Co., Ltd. Completed at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-23.

Sponsored by Nihon Pharmaceutical Co., Ltd · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Chinese patients who require gastrointestinal endoscopy will receive an intra-gastric single dose of NPO-11 20ml. The superiority of NPO-11 compared to placebo as a premedication for endoscopy will be verified in a randomized, double-blind, parallel-assignment design based on the proportion of patients having no gastric peristalsis.

The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions observed between informed consent and 7 days after administration in comparison with the placebo group.

02

Conditions studied

  • Patients Undergoing Gastrointestinal Endoscopy
03

In context

Lead sponsor

Nihon Pharmaceutical Co., Ltd is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are capable of understanding and complying with protocol requirements in the opinion of the investigator or the sub-investigator.
  2. Patients who are able to fill in the form.
  3. Patients who require gastrointestinal endoscopy using a scope of 9mm or greater diameter for follow-up of confirmed or investigation of a suspected upper gastrointestinal disease. (except for transnasal endoscopy and emergency endoscopy)
  4. Male or female chinese patients aged _18_ to _80
  5. Patients who agree to use routinely adequate from signing of informed consent to follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Patients have received any drug of other study within 120 days prior to providing their .
  2. Patients had been administered NPO-11 in the past.
  3. Patients who are the study site investigator or sub-investigator, an immediate family member (eg, spouse,parent, child, sibling), or may consent under duress.
  4. Patients have a history of upper gastrointestinal tract surgery.
  5. Patients have gastric stenosis or deformity that would make observation of peristaltic movement difficult.
  6. Patients have bleeding in the upper gastrointestinal tract and require hemostatic intervention.
  7. Patients have reflux esophagitis (defined as Los Angeles Class: B, C or D)
  8. Patients have an active gastric or duodenal ulcer (defined as Sakita-Miwa class: A1 or A2)
  9. Patients are on treatment (radiotherapy or chemotherapy) for cancer.
  10. Patient have decreased heart function ( heart function class: III or more)
  11. Patients have a history of shock, or allergies to l-menthol or peppermint oil.
  12. Patients have a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 12 months prior to the screening visit.
  13. Patients are required to take excluded medications.
  14. If female, patients are pregnant or lactating or intending to become pregnant from signing of informed consent to follow-up.
  15. Any subject who, in the opinion of the investigator or the sub-investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    NPO-11

    Drug: NPO-11

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of patients had no gastric peristalsis during the procedures

    No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.(central evaluation by independent evaluator)

    Time frame: 15 minutes

Secondary outcomes

  1. Change in peristaltic movement

    The measure use peristaltic grade(central evaluation by independent evaluator).

    Time frame: 15 minutes

  2. Difficulty level of intra-gastric observation

    Subjective evaluation by investigator or subinvestigator who performs endoscopy

    Time frame: 15 minutes

  3. Correlation between the time from the dose to the end of endoscopy and peristaltic grade

    Time frame: 15 minutes

07

Study locations

4 sites
  • East China
    East China, China
  • North China, China
  • Northwest China, China
  • South China, China
08

References and documents

Publications

  • Meng F, Li W, Zhi F, Li Z, Xue Z, He S, Chen W, Chen Y, Xing X, Yao C, Wu Y, Zhang S. Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study. Dig Endosc. 2021 Nov;33(7):1110-1119. doi: 10.1111/den.13941. Epub 2021 Apr 2. PubMed 33527576 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Aug 2018, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2017
First posted
Aug 28, 2017
StartActual
Aug 21, 2017
Primary completionActual
Aug 10, 2018
CompletionActual
Aug 17, 2018
Last update
Aug 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03263910
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Aug 28, 2017
Start date
Aug 21, 2017
Primary completion
Aug 10, 2018
Completion
Aug 17, 2018
Last update
Aug 23, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levomenthol · L-menthol Preparation NPO-11

Start the discussion